drugset / Trial / NCT07421284

A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia on a Background of Lipid-lowering Therapy

NCT07421284

Phase 3 Not yet recruiting 900 enrolled CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to compare the effectiveness, safety of SYH2053 in participants with primary hypercholesterolemia (non-familial) or mixed dyslipidemia on a background of lipid-lowering therapy. This trial plans to enroll 900 Participants.

Timeline

Start
2026-03-31
Primary completion
2027-12-31
Completion
2028-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject SYH2053 Unknown Subcutaneous

Indications